Full history for every metric is available with a Kvantra account
Enzychem Lifesciences Corporation (183490.KQ)
Key financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | KRW bn | 26 | 23 | 27 | 76 | 77 | 68 | 62 |
| Operating profit | KRW bn | -18 | -18 | |||||
| Net profit | KRW bn | -18 | -28 | -25 | -9 | -22 | -18 | -18 |
| EPS reported | KRW | -234.5 | -234.3 | |||||
| Operating cashflow per share | KRW | -129.5 | -134.6 | |||||
| Capex per share | KRW | 8.97 | 7.11 | |||||
| FCF per share | KRW | -138.4 | -141.7 | |||||
| Free cash flow | KRW bn | -12 | -11 | |||||
| Net debt | KRW bn | -88 | -98 | |||||
| Book value equity | KRW bn | 138 | 149 | |||||
| Book value per share | KRW | 1,617 | 1,886 | |||||
| Number of shares | m | 85.07 | 78.84 | |||||
| DPS (TTM paid) | KRW | 0.00 | 0.00 |
Financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.95 | 0.56 | |||||
| P/S LTM | x | 1.92 | 1.35 | |||||
| P/FCF LTM | x | -11.05 | -7.50 | |||||
| EV/EBITDA LTM | x | -8.40 | 1.30 | |||||
| EV/Sales LTM | x | 1.88 | -0.22 | |||||
| Earnings Yield LTM | % | -13.93% | -23.22% | |||||
| FCF Yield | % | -9.05% | -13.33% | |||||
| Quality | ||||||||
| ROE | % | -13.18% | -12.31% | |||||
| ROIC | % | -12.58% | -11.67% | |||||
| Operating margin | % | -26.97% | -29.77% | |||||
| Gross margin | % | 3.68% | 2.81% | |||||
| FCF/Sales | % | -17.38% | -18.06% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -12.44% | -18.52% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -2.43 | -1.96 | |||||
| Net Debt/EBITDA | x | 0.20 | 0.81 | |||||
| EBIT/Net interest | x | -90.69 | -97.31 | |||||
| Net debt/market cap | % | -67.58% | -116.48% | |||||
| Net debt/Equity | x | -0.64 | -0.66 | |||||
| Gross debt/equity | x | 0.04 | 0.04 | |||||
Company overview
Enzychem Lifesciences Corporation, a pharmaceutical company, primarily dedicates itself to formulating oral, small-molecule therapies aimed at addressing urgent unmet medical needs for patients in South Korea suffering from conditions in oncology, metabolic diseases, and inflammatory disorders. Furthermore, the firm is actively developing innovative treatments utilizing its EC-18 technology platform to combat chemotherapy-induced neutropenia, oral mucositis triggered by chemoradiation therapy, and acute radiation syndrome. Founded in 1999, its headquarters are situated in Seoul, South Korea.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Enzychem Lifesciences Corporation (183490.KQ)
Enzychem Lifesciences Corporation, a pharmaceutical company, primarily dedicates itself to formulating oral, small-molecule therapies aimed at addressing urgent unmet medical needs for patients in South Korea suffering from conditions in oncology, metabolic diseases, and inflammatory disorders. Furthermore, the firm is actively developing innovative treatments utilizing its EC-18 technology platform to combat chemotherapy-induced neutropenia, oral mucositis triggered by chemoradiation therapy, and acute radiation syndrome. Founded in 1999, its headquarters are situated in Seoul, South Korea.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free